摘要
目的探讨阿帕替尼联合调强适形放射治疗(IMRT)治疗肝转移癌的临床疗效及预后情况。方法选取接受阿帕替尼联合IMRT进行治疗的30例肝转移癌患者,观察其临床疗效和生存情况,分析其临床特征与预后的关系。结果30例肝转移癌患者接受阿帕替尼联合IMRT后,8例患者达到部分缓解(PR),15例患者达到疾病稳定(SD),7例患者治疗后1个月复查病情达疾病进展(PD)。全部患者的ORR为26.7%(8/30),DCR为76.7%(23/30)。截至随访结束,30例肝转移癌患者的中位总生存期(OS)为18个月(95%CI:12.76~27.24),中位无进展生存期(PFS)为7个月(95%CI:3.18~10.82)。全部患者的不良反应总发生率为43.3%(13/30)。Cox比例风险模型分析结果显示,肝转移灶数目是肝转移癌患者预后的独立影响因素。结论阿帕替尼联合IMRT治疗肝转移癌具有较高的肿瘤局部控制率,且患者对不良反应均可耐受,肝转移灶数目是影响肝转移癌患者预后的重要因素。
Objective To evaluate the efficacy and prognosis of apatinib combined with intensity-modulated radiation therapy(IMRT)in the treatment of metastatic liver cancer.Method A retrospective analysis was performed for 30 patients with metastatic liver cancer.All patients received treatment of IMRT combined with apatinib,the therapeutic effect and survival of all patients were observed,besides,the relationship with the clinical characteristics and prognosis was investigated.Result Among the 30 cases patients with metastatic liver cancer that were treated by apatinib and IMRT combination therapy,8 cases achieved partial response(PR),and 15 cases had stable disease(SD),while 7 cases developed progressive disease(PD)in 1-month visit after treatment.The objective response rate(ORR)and disease control rate(DCR)were 26.7%(8/30)and 76.7%(23/30)for all patients,respectively.As of the end of follow-up,the median overall survival(OS)and progression-free survival(PFS)in all patients were 18 months(95%CI:12.76-27.24)and 7 months(95%CI:3.18-10.82),respectively.The overall incidence rate of adverse reactions attained 43.3%(13/30).Cox proportional hazard model revealed that the number of liver metastases was the factor influencing the prognosis of metastatic liver cancer patients.Conclusion Apatinib combined with IMRT demonstrates relatively high local DCR and is well tolerated among metastatic liver cancer patients,notably,the number of liver metastases is an essential factor associated with the prognosis of patients with metastatic liver cancer.
作者
杨攀
陈灿
冉凤伟
曾甜
张艳玲
YANG Pan;CHEN Can;RAN Fengwei;ZENG Tian;ZHANG Yanling(Department of Oncology,the First Hospital Affiliated to Army Medical University(Southwest Hospital),Chongqing 400038,China)
出处
《癌症进展》
2020年第3期275-278,310,共5页
Oncology Progress
基金
军事医学与战创伤救治临床新技术计划项目(SWH2016JSTSYB-35)
关键词
肝转移癌
阿帕替尼
调强适形放射治疗
疗效
预后
不良反应
metastatic liver cancer
apatinib
intensity-modulated radiation therapy
efficacy
prognosis
adverse reaction
